

Uitdagingen van stoppen met roken bij patiënten met COPD

Dr. Eva van Eerd, afdeling huisartsgeneeskunde, Maastricht UMC+

- 1.. Shahab L., Jarvis M.J., Britton J., West R. Prevalence, diagnosis and relation to tobacco dependence of chronic obstructive pulmonary disease in a nationally representative population sample. *Thorax*. **61**, 1043-1047 (2006).
2. Tonnesen P., Carrozzi L., Fagerstrom K.O., Gratziau C., Jimenez-Ruiz C., Nardini S., et al. Smoking cessation in patients with respiratory diseases: a high priority, integral component of therapy. *Eur Respir J*. **29**, 390-417 (2007).
3. van Eerd E.A., Risor M.B., van Rossem C.R., van Schayck O.C., Kotz D. Experiences of tobacco smoking and quitting in smokers with and without chronic obstructive pulmonary disease-a qualitative analysis. *BMC Fam Pract*. **16**, (2015).
4. van Eerd E.A., van Rossem C.R., Spigt M.G., Wesseling G., van Schayck O.C., Kotz D. Do we need tailored smoking cessation interventions for smokers with COPD? A comparative study of smokers with and without COPD regarding factors associated with tobacco smoking. *Respiration*. **90**, 211-219 (2015).
5. van Eerd E.A.M., van Schayck O.C.P., Wesseling G., Kotz D. Predictors of long-term smoking cessation in patients with COPD: results from a randomised controlled trial. *The European respiratory journal*. **49**, (2017).
6. van Eerd E.A.M., Bech Risor M., Spigt M., Godycki-Cwirko M., Andreeva E., Francis N., et al. Why do physicians lack engagement with smoking cessation treatment in their COPD patients? A multinational qualitative study. *NPJ Prim Care Respir Med*. **27**, 41 (2017).

De Ziektelastmeter in de dagelijkse praktijk: Een instrument voor 'Zorg op maat'

Referenties

¹ Slok AHM, in 't Veen JCCM, Chavannes NH, van der Molen T, Rutten-van Mölken MPMH, Kerstjens HAM, Salomé PL, Holverda S, Dekhuijzen PNR, Schuiten D, Asijee GM, van Schayck OCP. *Development of the Assessment of Burden of COPD tool: an integrated tool to measure the burden of COPD*. npj Primary Care Respiratory Medicine. 2014;24 (Published online 10 July 2014).

¹ Slok AHM, in 't Veen JCCM, Chavannes NH, van der Molen T, Rutten-van Mölken MPMH, Kerstjens HAM, Asijee, GM, Salomé PL, Holverda S, Dekhuijzen PNR, Schuiten D, van Breukelen G, Kotz D, van Schayck OCP. *Effectiveness of the Assessment of Burden of Chronic Obstructive Pulmonary Disease (ABC) tool: study protocol of a cluster randomised trial in primary and secondary care*. BMC Pulm Med. 2014;14:131.

³¹ Slok AHM, Bemelmans TCH, Kotz D, van der Molen T, Kerstjens HAM, In 't Veen JCCM, Chavannes NH, Asijee GM, Rutten-van Molken MPMH, Schayck, OCP. *The Assessment of Burden of COPD (ABC) scale: a reliable and valid questionnaire*. COPD: Journal Of Chronic Obstructive Pulmonary Disease. Published Online Jan 20 2016; 1-8.

Scholing: Diagnose COPD en dan...? De Film.

www.youtube.com/watch?v=EAD8XuhQQ5k

(On)verantwoord gebruik van inhalatie-corticosteroïden bij patiënten met COPD

Prof. Dr. Onno C.P. van Schayck¹, Prof. Dr. Geertjan Wesseling², Dr. JanWillem Kocks³, Dr. Tjard Schermer⁴, Prof. Dr. Niels Chavannes⁵

1. Department of Family Medicine, CAPHRI, Maastricht University Netherlands
2. Department of Pulmonology, CAPHRI, Maastricht UMC +, Netherlands
3. Department of General Practice and Elderly Care Medicine, UMC Groningen, Netherlands
4. Department of General Practice, Radboud Universitair Medisch Centrum, Netherlands
5. Department of Public Health and Primary Care, Leids Universitair Medisch Centrum, Netherlands

referenties

1. Snoeck-Stroband JB, Schermer TR, Van Schayck CP, Muris JW, Van der Molen T, In't Veen JCCM, Chavannes NH, Broekhuizen BDL, Barnhoorn MJM, Smeele I, Geijer RMM, Tuut MK. NHG guideline COPD (third revision). *Huisarts Wet.* 2015;58(4):198-211.
2. Lucas AE, Smeenk FW, Smeele IJ, Van Schayck CP. Overtreatment with inhaled corticosteroids and diagnostic problems in primary care patients, an exploratory study. *Family practice.* 2008 Feb 27;25(2):86-91.
3. Singh S, Amin AV, Loke YK. Long-term use of inhaled corticosteroids and the risk of pneumonia in chronic obstructive pulmonary disease: a meta-analysis. *Archives of internal medicine.* 2009 Feb 9;169(3):219-29.
4. Suissa S, Kezouh A, Ernst P. Inhaled corticosteroids and the risks of diabetes onset and progression. *Am J Med* 2010;123(11):1001-06
5. Price DB, Russell R, Mares R, Burden A, Skinner D, Mikkelsen H, Ding C, Brice R, Chavannes NH, Kocks JW, Stephens JW. Metabolic Effects Associated with ICS in Patients with COPD and Comorbid Type 2 Diabetes: A Historical Matched Cohort Study. *PloS one.* 2016 Sep 22;11(9):e0162903.
6. Schermer TR, Hendriks AJ, Chavannes NH, Dekhuijzen PN, Wouters EF, Van den Hoogen H, van Schayck CP, Van Weel C. Probability and determinants of relapse after discontinuation of inhaled corticosteroids in patients with COPD treated in general practice. *Primary Care Respiratory Journal.* 2004 Mar 31;13(1):48-55.
7. Magnussen H, Disse B, Rodrikuez-Roisin R, Kirsten A, Watz H, et al. Withdrawal of Inhaled Glucocorticoids and Exacerbations of COPD. *N Engl J Med.* 2014 Oct 2;371(14):1285-94.
8. Wedzicha JA, Banerji D1, Chapman KR1, Vestbo J1, Roche N1, Ayers RT, et al., Indacaterol-Glycopyrronium versus Salmeterol-Fluticasone for COPD. *N Engl J Med.* 2016 Jun 9;374(23):2222-34
9. From the Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2017. Available from: <http://goldcopd.org>.
10. IPCRG Desktop Helper:
<http://www.theipcr.org/display/TreatP/Desktop+helper+6%3A+Evaluation+of+appropriate+ness+of+inhaled+corticosteroid+%28ICS%29+therapy+in+COPD+and+guidance+on+ICS+with+drawal>